Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report

Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report

Abstract Background The nucleotide reverse transcriptase inhibitor Tenofovir Alafenamide (TAF) is a novel pro-drug of tenofovir (TFV) and possesses a superior renal safety profile compared with tenofovir disoproxil fumerate (TDF). Due to unique pharmacokinetic characteristics, treatment with TAF is...

Full description

Bibliographic Details
Main Authors:	Jack E. Heron, Mark Bloch, Vinay Vanguru, John Saunders, David M. Gracey
Format:	Article
Language:	English
Published:	BMC 2020-08-01
Series:	BMC Nephrology
Subjects:	Fanconi syndrome Tenofovir alafenamide Antiretroviral therapy Nephrotoxicity Case report
Online Access:	http://link.springer.com/article/10.1186/s12882-020-01981-9

Similar Items

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Tenofovir alafenamide nephrotoxicity: a case report and literature review
by: Thornthun Ueaphongsukkit, et al.
Published: (2021-08-01)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
by: Dane Turner, et al.
Published: (2019-12-01)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
by: Tomoya Sano, et al.
Published: (2021-03-01)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
by: Linden Lalley-Chareczko, et al.
Published: (2020-03-01)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017-11-01)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021-08-01)

Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study
by: Thomas C.S. Martin, et al.
Published: (2020-11-01)

Incidence and association of renal dysfunction with a long term Tenofovir-based therapy among HIV-positive naïve cohort at Ronald Ross Hospital
by: Enock Wantakisha, et al.
Published: (2020-06-01)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
by: Kento Inada, et al.
Published: (2021-09-01)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018-10-01)

Efficacy of tenofovir alafenamide in treatment of hepatitis B virus: A meta-analysis and non-inferiority evaluation
by: Qiu-Ran Wang, et al.
Published: (2021-06-01)

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
by: Pierre-Emmanuel Plum, et al.
Published: (2021-09-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity
by: Rachel A. Murphy, et al.
Published: (2017-03-01)

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
by: Hannes Lengauer, et al.
Published: (2020-04-01)

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients
by: Brian T Lee, et al.
Published: (2021-02-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice
by: Eungyeong Jang, et al.
Published: (2020-10-01)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
by: Ashana Puri, et al.
Published: (2019-04-01)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
by: Manjula Gunawardana, et al.
Published: (2020-11-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form
by: Tej Kumar Kokkirala, et al.
Published: (2019-12-01)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
by: Ruochan Chen, et al.
Published: (2021-07-01)

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments
by: Simone Perazzolo, et al.
Published: (2020-12-01)

Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir
by: Pedro Magalhães-Costa, et al.

On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate: A Metastable Phase Featuring a Mixture of Co-Crystal and Salt
by: Jian-Wei Wang, et al.
Published: (2020-12-01)

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
by: Linying Li, et al.
Published: (2020-11-01)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
by: Chua Arlene C, et al.
Published: (2012-06-01)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
by: Leah M. Johnson, et al.
Published: (2019-07-01)

Tenofovir induced Fanconi syndrome: A rare cause of hypokalemic paralysis
by: E P Venkatesan, et al.
Published: (2014-01-01)

Effect of tenofovir Administration And Withdrawl On The Kidney Tissues Of Adult Male Albino Rats And The Protective Role Of Vitamin E
by: Rasha M. Abd El-Fattah, et al.
Published: (2019-07-01)

Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-β1/Smad3 signaling pathway
by: Lingxia Li, et al.
Published: (2019-07-01)

Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use
by: Mana Rao, et al.
Published: (2021-05-01)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
by: Daniel Yilma, et al.
Published: (2020-08-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Tenofovir-induced quadriparesis
by: Ashalatha Muppur, et al.
Published: (2020-01-01)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
by: Iman G.Al-Rakhat, et al.
Published: (2019-12-01)